Effect of moxidectin on CYP3A4 activity as evaluated by oral midazolam pharmacokinetics in healthy subjects

By  

Clinical Pharmacology In Drug Development, Vol. 3, Iss. 2, 2014-03 ,pp. : 151-157

John Wiley & Sons Inc

Access to resources Recommend Favorite

The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects

By Xu Hong-Rong   Chen Wei-Li   Li Xue-Ning   Chu Nan-Nan  

Pharmaceutical Biology (Formerly International Journal of Pharmacognosy), Vol. 48, Iss. 8, 2010-08 ,pp. : 947-952

Informa Healthcare

Access to resources Recommend Favorite

Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects

By Sabia Helene   Sunkara Gangadhar   Ligueros-Saylan Monica   Wang Yibin   Smith Harold   McLeod James   Prasad Pratapa  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 6, 2004-09 ,pp. : 407-412

Springer Publishing Company

Access to resources Recommend Favorite

The effect of lansoprazole, an OCT inhibitor, on metformin pharmacokinetics in healthy subjects

By Ding Yi   Jia YanYan   Song Ying   Lu ChengTao   Li YuWen   Chen MinChun   Wang MingMing   Wen AiDong  

European Journal of Clinical Pharmacology, Vol. 70, Iss. 2, 2014-02 ,pp. : 141-146

Springer Publishing Company

Access to resources Recommend Favorite

The effect of paroxetine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects

By Kadokura Takeshi   Adel Martin   Krauwinkel Walter   Takeshige Tetsuo   Nishida Akito  

European Journal of Clinical Pharmacology, Vol. 64, Iss. 6, 2008-06 ,pp. : 605-609

Springer Publishing Company

Access to resources Recommend Favorite